Sun Pharmaceutical Industries has received four observations from United States Food and Drug Administration (USFDA) for its Halol facility in Gujarat. The company will submit its response on the observations to the USFDA within 15 business days. The company is committed to addressing these observations promptly.
The United States Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAl) of company’s Halol facility from June 3 to June 11, 2019.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.